1
NSG 6005 WEEK 1-10 QUIZ / NSG6005 WEEK 1-10 QUIZ (LATEST): SOUTH
UNIVERSITY (ALREADY GRADED A)
1. A 68-year-old patient with hypertension, chronic kidney disease, and
osteoarthritis is prescribed a medication that undergoes extensive hepatic
metabolism before reaching systemic circulation. The patient asks why the same
medication may require a different dose than a younger adult with normal organ
function. Which pharmacokinetic concept best explains the influence of hepatic
metabolism on the amount of active medication reaching systemic circulation?
A. Renal tubular secretion
B. Protein binding
C. First-pass metabolism
D. Volume of distribution
Answer: A
2. A 45-year-old patient begins a medication that is highly lipid soluble and rapidly
distributes into adipose tissue. Several days later, the patient continues to have
measurable drug concentrations despite discontinuing therapy. Which
pharmacokinetic characteristic most directly explains this prolonged persistence?
A. Increased renal clearance
B. Large volume of distribution
C. Reduced protein binding
D. Rapid gastrointestinal absorption
Answer: B
3. A patient with significant hypoalbuminemia is prescribed a medication that is
normally highly protein bound. The clinician recognizes that a reduction in
albumin may increase the amount of unbound medication available to exert
pharmacologic effects. Which statement best describes this situation?
A. Only the bound drug produces pharmacologic effects
B. Hypoalbuminemia always decreases the medication's half-life
,2
C. Reduced binding may increase the free fraction of the medication
D. Protein binding has no influence on drug activity
Answer: C
4. A patient takes a medication with a half-life of approximately 12 hours. The
nurse practitioner explains that repeated dosing will gradually increase drug
concentrations until elimination and administration reach a relatively stable
relationship. Which term describes this condition?
A. Therapeutic index
B. Loading dose
C. First-pass effect
D. Steady state
Answer: D
5. A patient with severe renal impairment is prescribed a medication that is
primarily eliminated unchanged through the kidneys. Which pharmacokinetic
consideration is most important before initiating therapy?
A. The medication may require dosage adjustment based on renal function
B. Renal impairment will always increase gastrointestinal absorption
C. The medication will automatically become inactive
D. Kidney disease eliminates the need for therapeutic monitoring
Answer: A
6. A patient receives an intravenous medication and experiences a therapeutic
response almost immediately. Compared with an orally administered formulation
of the same drug, which characteristic most directly explains the rapid onset?
A. Increased hepatic metabolism
B. Direct entry into systemic circulation
C. Greater gastrointestinal protein binding
D. Delayed renal elimination
Answer: B
, 3
7. A medication produces its effects by binding to a receptor and activating a
cellular response similar to that produced by an endogenous ligand. Which
pharmacodynamic description best applies?
A. Competitive antagonist
B. Partial inverse agonist
C. Agonist
D. Enzyme inducer
Answer: C
8. A patient receives a medication that binds to a receptor but prevents the
normal ligand from activating it. Which pharmacologic action is most consistent
with this medication?
A. Receptor antagonism
B. Increased bioavailability
C. Enzyme induction
D. Renal secretion
Answer: A
9. A patient taking a medication develops a response that reaches a plateau
despite progressively increasing doses. Which pharmacodynamic concept
describes the maximum response a drug can produce?
A. Potency
B. Bioavailability
C. Efficacy
D. Clearance
Answer: C
10. Two medications are being compared for treatment of the same condition.
Medication A produces the desired effect at a lower dose than Medication B, but
both can ultimately produce the same maximum response. Which pharmacologic
characteristic is greater for Medication A?
NSG 6005 WEEK 1-10 QUIZ / NSG6005 WEEK 1-10 QUIZ (LATEST): SOUTH
UNIVERSITY (ALREADY GRADED A)
1. A 68-year-old patient with hypertension, chronic kidney disease, and
osteoarthritis is prescribed a medication that undergoes extensive hepatic
metabolism before reaching systemic circulation. The patient asks why the same
medication may require a different dose than a younger adult with normal organ
function. Which pharmacokinetic concept best explains the influence of hepatic
metabolism on the amount of active medication reaching systemic circulation?
A. Renal tubular secretion
B. Protein binding
C. First-pass metabolism
D. Volume of distribution
Answer: A
2. A 45-year-old patient begins a medication that is highly lipid soluble and rapidly
distributes into adipose tissue. Several days later, the patient continues to have
measurable drug concentrations despite discontinuing therapy. Which
pharmacokinetic characteristic most directly explains this prolonged persistence?
A. Increased renal clearance
B. Large volume of distribution
C. Reduced protein binding
D. Rapid gastrointestinal absorption
Answer: B
3. A patient with significant hypoalbuminemia is prescribed a medication that is
normally highly protein bound. The clinician recognizes that a reduction in
albumin may increase the amount of unbound medication available to exert
pharmacologic effects. Which statement best describes this situation?
A. Only the bound drug produces pharmacologic effects
B. Hypoalbuminemia always decreases the medication's half-life
,2
C. Reduced binding may increase the free fraction of the medication
D. Protein binding has no influence on drug activity
Answer: C
4. A patient takes a medication with a half-life of approximately 12 hours. The
nurse practitioner explains that repeated dosing will gradually increase drug
concentrations until elimination and administration reach a relatively stable
relationship. Which term describes this condition?
A. Therapeutic index
B. Loading dose
C. First-pass effect
D. Steady state
Answer: D
5. A patient with severe renal impairment is prescribed a medication that is
primarily eliminated unchanged through the kidneys. Which pharmacokinetic
consideration is most important before initiating therapy?
A. The medication may require dosage adjustment based on renal function
B. Renal impairment will always increase gastrointestinal absorption
C. The medication will automatically become inactive
D. Kidney disease eliminates the need for therapeutic monitoring
Answer: A
6. A patient receives an intravenous medication and experiences a therapeutic
response almost immediately. Compared with an orally administered formulation
of the same drug, which characteristic most directly explains the rapid onset?
A. Increased hepatic metabolism
B. Direct entry into systemic circulation
C. Greater gastrointestinal protein binding
D. Delayed renal elimination
Answer: B
, 3
7. A medication produces its effects by binding to a receptor and activating a
cellular response similar to that produced by an endogenous ligand. Which
pharmacodynamic description best applies?
A. Competitive antagonist
B. Partial inverse agonist
C. Agonist
D. Enzyme inducer
Answer: C
8. A patient receives a medication that binds to a receptor but prevents the
normal ligand from activating it. Which pharmacologic action is most consistent
with this medication?
A. Receptor antagonism
B. Increased bioavailability
C. Enzyme induction
D. Renal secretion
Answer: A
9. A patient taking a medication develops a response that reaches a plateau
despite progressively increasing doses. Which pharmacodynamic concept
describes the maximum response a drug can produce?
A. Potency
B. Bioavailability
C. Efficacy
D. Clearance
Answer: C
10. Two medications are being compared for treatment of the same condition.
Medication A produces the desired effect at a lower dose than Medication B, but
both can ultimately produce the same maximum response. Which pharmacologic
characteristic is greater for Medication A?
